Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) FCF Margin (2022 - 2025)

TriSalus Life Sciences' FCF Margin history spans 4 years, with the latest figure at 18.85% for Q4 2025.

  • For Q4 2025, FCF Margin rose 5441.0% year-over-year to 18.85%; the TTM value through Dec 2025 reached 40.04%, up 9990.0%, while the annual FY2025 figure was 40.04%, 9990.0% up from the prior year.
  • FCF Margin reached 18.85% in Q4 2025 per TLSIW's latest filing, up from 26.9% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 18.85% in Q4 2025 to a low of 583.23% in Q3 2022.
  • Average FCF Margin over 4 years is 193.35%, with a median of 168.12% recorded in 2024.
  • The largest YoY upside for FCF Margin was 27468bps in 2024 against a maximum downside of 1785bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 243.99% in 2022, then skyrocketed by 32bps to 166.91% in 2023, then surged by 56bps to 73.26% in 2024, then soared by 74bps to 18.85% in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's FCF Margin are 18.85% (Q4 2025), 26.9% (Q3 2025), and 64.45% (Q2 2025).